

\$1.3 BILLION NATIONAL HEALTH AND MEDICAL INDUSTRY GROWTH PLAN

Medical Technology, Biotechnology and Pharmaceutical (MTP) Sector

CURRENT SECTOR

HEALTH is an economic growth opportunity

- 7% of the economy
- 14% of workforce - one of the largest sectors
- 20% of Commonwealth expenditure
- Commonwealth policy leverage

MTP SECTOR

Companies

1,230

Jobs

> 62,000

184

Pharma/biotech

21,700



1,046

Medtech

17,700



+22,650 research jobs
supported by the sector

- **\$4.9b industry GVA** (2016, stable)
- **\$1.4b invested in R&D** (2016, stable)
- **\$5.2b in exports and growing** (2016,)
(10th largest, not directly linked to primary industries)
- **Upward trend in exports** (up 30% on FY15)
- **Reputation for research excellence**
(27,000 publications in 2016, up 3% from 2015)
- **1,357 clinical trials started in Australia**
(2015, estimated 65% public funded)
- **242 patents lodged** (2016)

GROWTH PLAN

GENOMICS AND PRECISION MEDICINE

Genomics Health Futures Mission

(\$500m / 10 years)

NEW TO WORLD INDUSTRIES

Frontier Research

(\$240m / 5 years)*

BioMedTech Horizons

(\$40m / 4 years)

Biomedical Translation Bridge

(\$22.3m / 5 years)*

Targeted Translation Research Accelerator

(\$125m / 9 years from 2019/20)*

INDUSTRY COLLABORATION

Industry Researcher Exchange

(\$32m / 4 years)*

Increased data linkage and release

(\$30m / 4 years ongoing)

Australian Medical Research Advisory

Board (\$20m / 4 years - MRFF and Industry Growth Plan)

CLINICAL TRIALS

Clinical Trials Activity

(\$206m / 5 years)**

International Clinical Trial Collaboration

(\$42m / 5 years)*

Clinical Trials National Front Door

(preliminary work to develop concept)

* MRFF committed via MYEFO 2017-18, but not announced.

** \$56M announced, with a further \$150M from 2019-20.

^ Estimates based on 'the size of the prize' assumptions in MTPConnect's Sector Competitiveness Plan (2016)

^^ Extrapolation of MRFF clinical trial investment to date.

Source: Australian Genomics Health Alliance, based on case studies in childhood syndromes.

FUTURE OUTLOOK (2030)

ECONOMIC WEALTH

4x new drug, device and therapeutic industries

- *ie, advanced wearables, nanotechnology, point-of-care diagnostics, and gene and cell therapy*

More high value and growing MTP companies

- *200 new MTP companies, increasingly ASX listed[^]*

Skilled and future-proofed jobs

- *28,000 new highly skilled MTP jobs, nearly 50% associated with research[^]*

\$18b cumulative additional nominal GVA[^]

Stronger researcher–industry collaboration

- *At least 300 new industry based medical researchers*

Global market leader in clinical trial provision

- *130 new clinical trials[^]*

Increasing MTP exports

- *50% increase in exports, new markets established[^]*

HEALTH WEALTH

Lives saved and transformed

Increased survivability and quality of life

Targeted treatments and better use of medicines

Improved diagnosis and avoided health costs

- *5-fold increase in diagnostic rate enabled by genomics[^]*
- *greater than 75% drop in diagnostic costs (27k to 6k)[#]*